PSC
CLCD

Piper Sandler & Co’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

Piper Sandler & Co’s Portfolio CLCD Stock Details CLCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5,215
Closed -$20K – 106
2015
Q3 		$20K Sell
5,215
-37,245
-88% -$275K 0.02% 98
2015
Q2 		$378K Buy
+42,460
New +$364K 0.23% 50

Other funds holding CLCD

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Piper Sandler & Co's CLCD Position: Q4 2015 in Review

Piper Sandler & Co sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q4 2015, closing a stake of 5,215 shares — an estimated $20K sold.

Piper Sandler & Co first reported a position in CLCD in Q2 2015 and held it in 2 quarters. The position peaked at $378K in Q2 2015. 21 funds tracked by Wall St. Rank hold CLCD as of Q4 2015.

  • Piper Sandler & Co reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 5,215 CoLucid Pharmaceuticals, Inc. shares in Q4 2015, an estimated $20K.
  • Piper Sandler & Co first reported a position in CoLucid Pharmaceuticals, Inc. in Q2 2015 and held it in 2 quarters.
  • Piper Sandler & Co's CoLucid Pharmaceuticals, Inc. position peaked at $378K in Q2 2015.
  • 21 funds tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q4 2015.

Based on Piper Sandler & Co's 13F filing for Q4 2015, filed 16 Feb 2016.